Lupin gets FDA nod for generic Acticlate

SILVER SPRING, Md. — The Food and Drug Administration has approved Lupin’s generic of Acticlate (doxycycline hyclate) tablets. The drug is indicated to treat infections caused by various micro-organisms and as an adjunctive therapy for severe acne.

Lupin’s generic will be available in 75- and 150-mg dosage strengths. The product had U.S. sales of roughly $253 million for the 12 months ended June 2017, according to QuintilesIMS data.